According to the starting dose, 35 CS patients, including 28 patients with ACTH-dependent CS, with UC > ULN were divided into two cohorts: in the first one (low dose, LD, group), starting dose was 100 mg/day, whereas in the second one (high dose, HD, group) starting dose was 250 mg/day. The gene discussed is POMC; the disease is Cowden syndrome 1.